Teleflex Incorporated (NYSE:TFX) Receives $182.63 Average Price Target from Analysts

Teleflex Incorporated (NYSE:TFX) has received an average rating of “Hold” from the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $182.63.

A number of analysts have recently weighed in on TFX shares. Morgan Stanley reduced their price target on shares of Teleflex from $275.00 to $191.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research note on Wednesday. Truist Financial reduced their price target on shares of Teleflex from $200.00 to $149.00 and set a “hold” rating for the company in a research note on Monday, March 3rd. Citizens Jmp lowered shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. Finally, Raymond James lowered shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th.

Teleflex Price Performance

NYSE TFX opened at $137.79 on Monday. Teleflex has a 52 week low of $128.55 and a 52 week high of $249.90. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37. The stock has a market cap of $6.39 billion, a price-to-earnings ratio of 27.39, a price-to-earnings-growth ratio of 1.73 and a beta of 1.21. The company has a 50-day moving average price of $166.99 and a two-hundred day moving average price of $197.99.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, topping the consensus estimate of $3.86 by $0.03. The firm had revenue of $795.40 million during the quarter, compared to analysts’ expectations of $813.24 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. Analysts forecast that Teleflex will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Friday, March 7th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.99%. The ex-dividend date is Friday, March 7th. Teleflex’s dividend payout ratio is presently 95.77%.

Institutional Investors Weigh In On Teleflex

Several hedge funds have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. lifted its position in shares of Teleflex by 4.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,173,121 shares of the medical technology company’s stock valued at $1,098,693,000 after acquiring an additional 261,279 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Teleflex by 2.8% in the 3rd quarter. Janus Henderson Group PLC now owns 5,376,452 shares of the medical technology company’s stock valued at $1,329,704,000 after acquiring an additional 147,147 shares in the last quarter. State Street Corp lifted its position in shares of Teleflex by 1.0% in the 3rd quarter. State Street Corp now owns 2,057,080 shares of the medical technology company’s stock valued at $508,757,000 after acquiring an additional 21,291 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Teleflex by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,138,867 shares of the medical technology company’s stock valued at $202,161,000 after acquiring an additional 8,307 shares in the last quarter. Finally, Cooke & Bieler LP increased its stake in Teleflex by 22.1% in the 4th quarter. Cooke & Bieler LP now owns 1,078,557 shares of the medical technology company’s stock valued at $191,962,000 after buying an additional 195,150 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.